Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 1.1 -0.01 (-0.9%) Market Cap: 281.12 Mil Enterprise Value: 163.71 Mil PE Ratio: 0 PB Ratio: 11.00 GF Score: 70/100

Q2 2020 Adaptimmune Therapeutics PLC Earnings Call Transcript

Aug 06, 2020 / 12:00PM GMT
Release Date Price: $8.06 (-7.57%)
Operator

Hello, and welcome to Adaptimmune Q2 financial and business update. With me on today's call is Juli Miller.

Juli, you may begin.

Juli P. Miller
Adaptimmune Therapeutics plc - Senior Director of IR

Good morning, and welcome to Adaptimmune's conference call to discuss our second quarter 2020 financial results.

I would ask you to please review the full text of our forward-looking statements from this morning's press release. We anticipate making projections during this call and actual results could differ materially due to a number of factors, including those outlined in our latest filings with the SEC.

Adrian Rawcliffe, our Chief Executive Officer, is with me for the prepared portion of this call, and other members of our management team will be available for Q&A.

With that, I'll turn the call over to Adrian Rawcliffe. Ad?

Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director

Thank you, Juli, and thank you, everyone, for joining

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot